Home / Research Library / BURN · Metabolic Pathway Research
BURN · Metabolic Pathway Research

5-Amino-1MQ: A Research Overview of the NNMT Inhibitor

2026-06-08 · ~2 min read · For laboratory and educational use only

All information here is for laboratory and educational research only. No compound referenced is approved for human or veterinary use, and nothing here is medical advice.

The short version
  • 5-Amino-1MQ is a small molecule (not a peptide) studied in metabolic research because it blocks an enzyme called NNMT, which is linked to NAD plus, a chemical cells use for energy.
  • The research is early and almost entirely in cells and animals. In mouse studies, compounds of this type reduced obesity caused by a high-fat diet, but these results have not been tested in people.
  • There are no published human trials, so there is no controlled human safety or effectiveness data. Online community reports about fat loss are personal anecdotes, not measured results.
  • It is not approved by the FDA for any use and is not an approved drug, supplement, or food ingredient.
  • BioRegen does not claim it works and sells it strictly for laboratory and educational research, not for human or veterinary use.

5-Amino-1MQ is a small molecule that scientists have started paying more attention to in metabolic research. It works by blocking an enzyme called NNMT (short for nicotinamide N-methyltransferase). An enzyme is just a protein that speeds up a chemical reaction in the body. This page explains, in plain terms, what blocking NNMT means, what published studies have looked at, and how researchers handle 5-Amino-1MQ in the lab. This information is for laboratory and educational purposes only. 5-Amino-1MQ is not approved for human or veterinary use.

What is NNMT, and why does it matter?

NNMT is an enzyme that helps the body process a vitamin building block called nicotinamide. Nicotinamide is one of the ingredients cells use to make NAD+, a molecule that helps cells turn food into energy. In published studies, when NNMT is very active, researchers have seen changes in how cells handle energy in their test models. So scientists study what happens when you slow NNMT down: it may change how much NAD+ is available and how cells send energy-related signals. That is the main reason researchers are interested in 5-Amino-1MQ.

What the research explores

Early research on 5-Amino-1MQ has looked at how it affects fat cells (the cells that store fat), how cells use energy, and NAD+ levels. This work has been done in animals and in cells, not in people. As with many newer research molecules, the science is still early and mostly done in the lab. So the results point in a direction worth studying, but they are not proof of anything yet.

How it differs from peptides

Most products discussed on this site are peptides, which are short chains of amino acids. 5-Amino-1MQ is different. It is a small molecule, not a peptide. That changes how researchers handle and store it in the lab. It also means it sits alongside, but is not the same as, the metabolic and repair peptides that researchers often work with.

Frequently asked questions

Is 5-Amino-1MQ a peptide?

No. It is a small molecule that blocks the NNMT enzyme. It is not a peptide. That said, researchers often study it in the same metabolic research projects as peptides.

What is the connection to NAD+?

Cells have a recycling route that helps them rebuild their NAD+ supply, sometimes called the NAD+ salvage pathway. Research suggests that by slowing down NNMT, 5-Amino-1MQ may affect that recycling route. Since NAD+ is so important for how cells make energy, this is an active area of study.


Explore related compounds in our metabolic research (BURN) collection or the full research catalog.

Selected research references

Reference metadata sourced via PubMed.

Disclaimer: All products and information provided by BioRegen are for laboratory and educational research purposes only. Nothing here is medical advice, and 5-Amino-1MQ is not approved for human or veterinary use.

The evidence spectrum

The full research picture, clearly labeled

BioRegen reports the entire research landscape for this compound across four clearly separated tiers, strongest evidence first. Lower tiers, including community and anecdotal reports, are labeled as such and are not BioRegen claims.

Clinical Human trials

No human clinical trials of 5-Amino-1MQ have been reported in the peer-reviewed literature to date. There is therefore no controlled human efficacy or safety data on which to draw, and any account of human effects would be speculative. Investigators describe the molecule as research-stage, with the existing evidence base confined to laboratory and animal models rather than registered trials.

Preclinical Lab and animal

5-Amino-1MQ is described in published research as a small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme implicated in NAD+ salvage and cellular metabolism. Neelakantan and colleagues reported that selective, membrane-permeable small-molecule NNMT inhibitors of this class reversed high-fat-diet-induced obesity in mice (Neelakantan et al., Biochemical Pharmacology, 2018, doi:10.1016/j.bcp.2017.11.007). This builds on earlier work by Kraus and colleagues, who reported that NNMT knockdown protected mice against diet-induced obesity (Kraus et al., Nature, 2014, doi:10.1038/nature13198). These findings are from cell and rodent models and have not been extended to humans.

Anecdotal Community, unverified

Within fat-loss and NAD-focused biohacker communities and longevity forums, 5-Amino-1MQ is discussed as a metabolism and body-composition compound, often in connection with NAD+ support. Such discussion reflects individual self-experimentation and online commentary rather than measured outcomes, and these venues are not a substitute for the controlled preclinical record. Reports of this kind are unverified anecdotal commentary, not controlled data, and not a BioRegen claim.

Regulatory Approval status

5-Amino-1MQ is not approved by the FDA for any use and is not an approved drug, dietary supplement, or food ingredient. It carries no recognized therapeutic indication and has not undergone regulatory review for human administration. BioRegen supplies it strictly for laboratory and educational research, not for human use.

Tiers are evidence categories, not endorsements. Clinical and preclinical entries summarize third-party published research. Community and anecdotal entries are unverified reports discussed by others, not findings and not BioRegen claims. Nothing here is medical advice, and no compound is approved for human or veterinary use except where explicitly stated under Regulatory status.

In the catalog

Shop this research material

Related research

More peptide research to explore

Explore the research line

Browse the BioRegen catalog, or grab the free reference guide · create a free account for 10% off your first order.